KerryL(Massman)ReynoldsMD

Oncology • Boston, MA

Clinical Fellow in Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Reynolds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reynolds' full profile

Already have an account?

Office
101 Nicolls Rd
Boston, MA 11794
Phone+1 617-726-2862

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
University of Missouri-Columbia School of MedicineClass of 2008

Certifications & Licensure

MA State Medical License 2011 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Double Trouble: A Case Series on Dual Morphology Cutaneous Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Joseph Ebriani, Mike Westmeijer, Bethany Brumbaugh, Allison Holt, Baraa Hijaz
International Journal of Dermatology. 2025-03-21
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.
Maysa Vilbert, Leyre Zubiri, Meghan J Mooradian, Kerry L Reynolds
JCO Oncology Practice. 2025-03-01
Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multicenter retrospective cohort study.
Baraa A Hijaz, Natalie Braun, Kerry L Reynolds, Yevgeniy R Semenov, Nicole R LeBoeuf
Journal of the American Academy of Dermatology. 2025-02-28

Journal Articles

Cost-Effectiveness of Pembrolizumab plus Axitinib vs Nivolumab plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Kerry (Massman) Reynolds, MD, JAMA Network Open

Lectures

Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trend...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Researchers Shed Light on Why Cancer Immunotherapies Sometimes Harm HeartNovember 8th, 2024
Mechanisms Behind Myocarditis in Cancer Patients Treated with Immune Checkpoint Inhibitors FoundNovember 6th, 2024
Study Reveals How Cancer Immunotherapy Leads to Deadly Form of Heart Inflammation in Some PatientsNovember 6th, 2024
Join now to see all